You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Trelegy Ellipta

What is Trelegy Ellipta?

Trelegy Ellipta is indicated as a maintenance treatment in adult patients with moderate to severe COPD who are not adequately treated by a combination of an inhaled corticosteroid (ICS) and a long-acting β2-agonist (LABA) or a combination of a long-acting muscarinic antagonist (LAMA) and a long-acting β2-agonist (LABA).

Trelegy Ellipta contains three active substances; an inhaled corticosteroid (fluticasone furoate) and two bronchodilators (umeclidinium and vilanterol). 1

Safety information

For safety information on Trelegy Ellipta including information on who is suitable for a Trelegy prescription, please see the Trelegy Ellipta patient information leaflet link below.

References:

  1. Trelegy Ellipta patient information leaflet

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. If you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard.
By reporting side effects you can help provide more information on the safety of this medicine.

Trelegy and Ellipta are registered trademarks of the GlaxoSmithKline group of companies